NEUROCRINE BIOSCIENCES INC (NBIX)
US64125C1099 - Common Stock
Overall NBIX gets a fundamental rating of 8 out of 10. We evaluated NBIX against 577 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making NBIX a very profitable company, without any liquidiy or solvency issues. NBIX is evaluated to be cheap and growing strongly. This does not happen too often! These ratings would make NBIX suitable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
NBIX had positive earnings in the past year.
In the past year NBIX had a positive cash flow from operations.
Each year in the past 5 years NBIX has been profitable.
NBIX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 10.65%, NBIX belongs to the top of the industry, outperforming 97.56% of the companies in the same industry.
NBIX has a Return On Equity of 15.49%. This is amongst the best in the industry. NBIX outperforms 97.21% of its industry peers.
NBIX's Return On Invested Capital of 12.56% is amongst the best of the industry. NBIX outperforms 96.86% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for NBIX is below the industry average of 14.68%.
The 3 year average ROIC (9.89%) for NBIX is below the current ROIC(12.56%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.65% | ||
| ROE | 15.49% | ||
| ROIC | 12.56% |
ROA(3y)6.18%
ROA(5y)8.97%
ROE(3y)8.92%
ROE(5y)13.75%
ROIC(3y)9.89%
ROIC(5y)11.96%
1.3 Margins
Looking at the Profit Margin, with a value of 18.65%, NBIX belongs to the top of the industry, outperforming 97.56% of the companies in the same industry.
NBIX's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 23.73%, NBIX belongs to the top of the industry, outperforming 97.56% of the companies in the same industry.
NBIX's Operating Margin has improved in the last couple of years.
NBIX has a Gross Margin of 98.05%. This is amongst the best in the industry. NBIX outperforms 98.08% of its industry peers.
NBIX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.73% | ||
| PM (TTM) | 18.65% | ||
| GM | 98.05% |
OM growth 3Y-12.58%
OM growth 5Y20.67%
PM growth 3Y-30.22%
PM growth 5Y23.12%
GM growth 3Y-0.38%
GM growth 5Y-0.21%
2. Health
2.1 Basic Checks
NBIX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
NBIX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for NBIX has been increased compared to 5 years ago.
Compared to 1 year ago, NBIX has an improved debt to assets ratio.
2.2 Solvency
NBIX has an Altman-Z score of 9.47. This indicates that NBIX is financially healthy and has little risk of bankruptcy at the moment.
NBIX's Altman-Z score of 9.47 is amongst the best of the industry. NBIX outperforms 84.15% of its industry peers.
There is no outstanding debt for NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.2 | ||
| Altman-Z | 9.47 |
ROIC/WACC1.18
WACC10.66%
2.3 Liquidity
NBIX has a Current Ratio of 2.52. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.
NBIX has a Current ratio of 2.52. This is in the lower half of the industry: NBIX underperforms 72.30% of its industry peers.
NBIX has a Quick Ratio of 2.47. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.47, NBIX is doing worse than 71.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.52 | ||
| Quick Ratio | 2.47 |
3. Growth
3.1 Past
NBIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 505.00%, which is quite impressive.
Measured over the past years, NBIX shows a very strong growth in Earnings Per Share. The EPS has been growing by 70.09% on average per year.
The Revenue has grown by 23.99% in the past year. This is a very strong growth!
NBIX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 33.13% yearly.
EPS 1Y (TTM)505%
EPS 3Y23.01%
EPS 5Y70.09%
EPS Q2Q%153.16%
Revenue 1Y (TTM)23.99%
Revenue growth 3Y21.74%
Revenue growth 5Y33.13%
Sales Q2Q%22.57%
3.2 Future
NBIX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.72% yearly.
Based on estimates for the next years, NBIX will show a quite strong growth in Revenue. The Revenue will grow by 15.24% on average per year.
EPS Next Y71.41%
EPS Next 2Y63.69%
EPS Next 3Y54.25%
EPS Next 5Y44.72%
Revenue Next Year17.54%
Revenue Next 2Y16.38%
Revenue Next 3Y16.4%
Revenue Next 5Y15.24%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 40.25 indicates a quite expensive valuation of NBIX.
Based on the Price/Earnings ratio, NBIX is valued cheaply inside the industry as 95.12% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 24.29. NBIX is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 22.53, NBIX is valued on the expensive side.
Based on the Price/Forward Earnings ratio, NBIX is valued cheaply inside the industry as 94.43% of the companies are valued more expensively.
NBIX is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 20.35, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.25 | ||
| Fwd PE | 22.53 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NBIX is valued cheaply inside the industry as 95.30% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, NBIX is valued cheaply inside the industry as 97.74% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 23.93 | ||
| EV/EBITDA | 25.97 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NBIX has an outstanding profitability rating, which may justify a higher PE ratio.
NBIX's earnings are expected to grow with 54.25% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.56
PEG (5Y)0.57
EPS Next 2Y63.69%
EPS Next 3Y54.25%
5. Dividend
5.1 Amount
NBIX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NEUROCRINE BIOSCIENCES INC
NASDAQ:NBIX (7/25/2024, 7:02:17 PM)
After market: 146.1 0 (0%)146.1
+0.22 (+0.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap14.70B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.25 | ||
| Fwd PE | 22.53 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.56
PEG (5Y)0.57
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.65% | ||
| ROE | 15.49% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 23.73% | ||
| PM (TTM) | 18.65% | ||
| GM | 98.05% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.52 | ||
| Quick Ratio | 2.47 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)505%
EPS 3Y23.01%
EPS 5Y
EPS Q2Q%
EPS Next Y71.41%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)23.99%
Revenue growth 3Y21.74%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y